Grants and Contracts Details
to determine if pioglitazone, compared to placebo, will reduce the overall risk for fatal or non-fatal stroke or fatal or non-fatal MI among non-diabetic men and women over age 40 years with insulin resistance and a recent ischemic stroke or transient ischemic attack.
|Effective start/end date||9/1/12 → 8/31/14|
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.